Special considerations in the management of lower GI bleed by interventional radiology

Shihong Li, Brendan Oshea, Shiliang Sun *

University of Iowa Health Care, Department of Radiology, Division of Interventional Radiology. Iowa City, Iowa, 52242, USA

Abstract

Despite the rapid development of diagnostic and therapeutic modalities and techniques to manage LGIB patients from interventional radiology’s standpoint, a successful localization of the bleeding site that leads to an effective embolotherapy remains a significant technical challenge. The interventional radiologist’s decisions when managing patients with LGIB may significantly impact the clinical outcomes; therefore, management should be made based on careful and thorough considerations of factors such as etiology, locations, patient’s comorbidities, and potential post-procedure complications, among others. The purpose of this paper is to review the management of LGIB by interventional radiology, focusing on a few challenging and common clinical situations that require special consideration by interventional radiologists.

1. Introduction

Lower gastrointestinal bleeding (LGIB) refers to bleeding originating from the gastrointestinal tract distal to the ligament of Treitz, thus including the small intestine, colon, rectum or anus. LGIB accounts for approximately 20%–25% of all gastrointestinal hemorrhages, with a reported annual incidence of 21–27 per 100,000 populations, and a mortality rate of 2–4% in North America.1–3 Currently, conventional treatment options for LGIB include endoscopic therapy, transcatheter arterial embolization, and surgery. Colonoscopy is considered the best management tool for patients with chronic and intermittent LGIB but is less reliable when treating patients with severe, life-threatening hematochezia due to inadequate visualization caused by inadequate bowel preparation or active bleeding. Indications for emergent surgery include life-threatening bleeding in patients who fail endoscopy and embolization treatments, generally as a last resort treatment option given the life-threatening bleeding in patients who fail endoscopy and embolization treatments, generally as a last resort treatment option given the life-threatening bleeding.4,5

With the development of coaxial microcatheters, super-selective embolization has emerged as a viable treatment option for LGIB and has demonstrated many advantages compared to endoscopic or surgical treatments.6 By using appropriate embolic agents, hemostasis in the lower gastrointestinal tract can be achieved rapidly and safely by decreasing arterial perfusion pressure to the bleeding site without causing complete devascularization.7 Thus, it has been widely used to treat acute and life-threatening LGIB and has become the treatment of choice in many cases.

Despite the rapid development of diagnostic and therapeutic modalities and techniques to manage LGIB patients from interventional radiology’s standpoint, a successful localization of the bleeding site that leads to an effective embolotherapy remains a significant technical challenge. The interventional radiologist’s decisions when managing patients with LGIB may significantly impact the clinical outcomes, therefore, management should be made based on careful and thorough considerations of factors such as etiology, locations, patient’s comorbidities, and potential post-procedure complications, among others. The purpose of this paper is to review the management of LGIB by interventional radiology, focusing on a few challenging and common clinical situations that require special considerations by interventional radiologists.

2. Angiographically occult LGIB and prophylactic embolotherapy

One of the most significant clinical challenges for interventional radiologists to manage LGIB is angiographically occult bleeding. In past decades there has been a significant evolution in the diagnostic and treatment modalities used to manage these patients by gastroenterologists, radiologists, and surgeons. However, the primary challenge of LGIB management remains the identification of the source rather than the treatment of bleeding.8 Accurate detection of LGIB by angiography requires a reported bleeding rate of at least 1 ml/min, thus a negative angiography is common in patients with LGIB given the intermittent

* Corresponding author.
E-mail addresses: Shihong.Li@emory.edu (S. Li), shiliang-sun@uiowa.edu (S. Sun).

https://doi.org/10.1016/j.jimed.2019.09.007

Available online 14 September 2019
2096-3602/© 2019 Shanghai Journal of Interventional Medicine Press. Production and hosting by Elsevier B.V. on behalf of KeAi. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
nature of bleeding. The overall yield of angiography for the detection of LGIB source ranges widely with success rates reported from 40%-78%.10 For bleeding patients without an identifiable angiographic source, a super-selective embolization is generally performed, and treatment options become very limited and challenging. If the patient remains hemodynamically stable, observation with supportive treatment is usually selected, despite a high rebleeding rate in untreated LGIB, especially when bleeding from diverticular disease or angiodysplasia.11

Once the bleeding recurs, the mortality rate may approach 30%.12 If the patient becomes hemodynamically unstable, emergency surgery may be indicated, with mortality rates as high as 33–57%.13,14

Provocative angiography may improve the diagnostic yield for LGIB. Several studies have reported that following a nonlocalized angiography, bleeding can be induced by using systemic heparinization and selective injection of a vasodilator with a thrombolytic.15–17 However, this approach remains controversial due to concerns of inducing uncontrolled bleeding and is usually reserved for LGIB patients with repeatedly negative angiographies.18 In upper gastrointestinal bleeding (UGIB), prophylactic embolization has proven to be effective.16,17 For example, Lang et al.16 reported successful treatment of massive UGIB by prophylactic embolization of the left gastric artery. Theoretically, prophylactic embolization could be a feasible alternative to treat angiographically occult LGIB as well, if source localization by pre-angiographic imaging studies such as nuclear scintigraphy or CT angiogram is sufficiently accurate. Few studies have been conducted to evaluate the efficacy of prophylactic embolization in LGIB to date. There are multiple factors for this paucity of data. LGIB is only one-fifth to one-third as common as UGIB. It generally has a more indolent clinical presentation and spontaneously stops in 80%-85% cases.19 Second, the left gastric artery is reported to be responsible for approximately 85% of the UGIB cases.19

The extensive collateral blood supply to the upper GI tract also allows relatively safe embolization of suspected vessels with low risk of end-organ ischemia. The bowel distal to the ligament of Treitz (except for the rectum) does not have a dual blood supply.19 The left gastric artery may be empirically embolized in the correct clinical setting, and there is a high likelihood of treating the bleeding source.20 Conversely, in angiographically occult bleeding within the lower GI tract, the end organ arterial distribution renders prophylactic embolization hazardous by producing bowel ischemia.

Our group recently conducted a retrospective study including 126 patients of LGIB for with mesenteric angiography performed during a 10 years period.21 Approximately one-third of the initial mesenteric angiographies demonstrated no identifiable bleeding source. Subsequently, a total of 18 patients underwent 24 prophylactic embolization procedures based on the pre-angiographic localization by nuclear scintigraphy. When compared to the angiographically occult LGIB patients who had no interventions, the patients who had prophylactic embolotherapy were found to have significantly decreased bleeding recurrence without increased risk of post-embolization bowel infarct, suggesting that prophylactic embolotherapy of LGIB may be valuable and safe in selected clinical populations. Future studies need to be performed to verify the safety and efficacy of prophylactic embolotherapy for angiographically occult LGIB, with focus on bleeding etiologies, anatomic location, comorbidities, and embolization techniques/agents (Fig. 1).

Pre-angiographic localization of LGIB is crucial for an effective prophylactic embolization of LGIB. Mesenteric angiography with potential embolization typically follows a positive pre-angiography Tc-99M RBC scan or CT angiogram, and occasionally both.14,15 If the initial mesenteric angiogram is negative, the decision is usually to observe and continue conservative treatment (16). However, our study suggested that with a sufficiently precise pre-angiography localization of the bleeding source, a prophylactic embolization can be performed to prevent recurrent bleeding effectively and may not increase the risk of bowel infarct compared to super-selective embolization. Although the American College of Radiology Appropriateness Criteria rates Tc-99M red blood cell (RBC) scintigraphy and CT angiogram equally appropriate, it remains controversial that which one is superior for pre-angiography screening in LGIB patients. Tc-99M RBC scan has been reported as a more sensitive test compared to CT angiogram, detecting bleeding at rates of as low as 0.1–0.4 ml/min, whereas CT angiogram is reported to be sensitive for source detection with rates of at least 0.5 ml/min.22 Importantly, Tc-99M RBC scintigraphy is helpful for intermittent bleeding because imaging is performed continuously during a 1–2 h period. As a result, scintigraphic screening increases the diagnostic yield of mesenteric

Fig. 1. (A-E), 49 years old male has anti-coagulation related lower GI bleeding. A. SMA arteriogram showed significant tissue stain/contrast extravasation, indicating active bleeding at the proximal jejunum (arrow). B. Sub-selective jejunal branch of SMA showed significant tissue stain, consistent with findings of angiodysplasia. C. Status post sub-selective micro-coils and Gel-foam slurry embolization of the jejunal branch of SMA with minimal residual tissue stain (arrow). D. CT angiogram one day post first embolization: active contrast extravasation again noted at proximal jejunum (arrow). E. Repeat mesenteric angiography: active bleeding localized from different segmental jejunal artery (arrow). F. Successful transcatheter embolization with micro-coils (arrow) with no further bleeding and complications.
angiography in patients who are not actively bleeding at the time of examination.\textsuperscript{22} However, a significant limitation for Tc-99M RBC scintigraphy is its poor ability to precisely localize the bleeding source, whereas a positive CT angiogram’s high spatial resolution may provide a clear roadmap to target angiography.\textsuperscript{19,22} Our institutional protocol for patients with clinical suspicion of LGIB, with or without a prior colonoscopy, is to perform a Tc-99M RBC scan to more precisely obtain pre-angiography localization of the bleeding source. Following a positive pre-angiography screening, it is critical to perform an angiography as quickly as reasonably possible, to increase the yield of angiography as suggested by literature.\textsuperscript{23} Future studies on prophylactic embolization treating LGIB should include evaluations of screening CT angiogram on its role of providing precise anatomic information of the bleeding source, which possibly results in safer and more effective prophylactic embolotherapy.

3. Management of LGIB in anticoagulation and LVAD recipients by interventional radiology

In the past decade, anticoagulation therapy has become a common therapy for variety patients, and also, a rapidly growing population of patients with end-stage heart disease have undergone left ventricular assist device (LVAD) implantation due to organ shortage. Currently, second generation LVAD - continuous-flow LVAD (CF LVAD) is widely used. Compared to first generation LVAD which were pulsatile volume-displacement devices, CF LVAD provides improved reliability and allows implantation in smaller patients,\textsuperscript{24} expanding the eligible patient population.

LGIB is a significant adverse event following LVAD implantation, its incidence in LVAD recipients is reported to range from 17.6\%-40\%.\textsuperscript{25,27} The higher risk does not appear entirely attributable to the aggressive anticoagulation therapy associated with LVAD use. A recent study showed a higher rate of GIB in LVAD recipients compared with patients receiving anticoagulation for cardiac valve replacement surgery.\textsuperscript{28} The underlying mechanism to account for increased bleeding risk beyond that of anticoagulation therapy remains unclear. Factors such as altered hemodynamics, reduced pulsatility, association with arteriovenous malformation (AVM), and acquired von Willebrand disease have been proposed as possible mechanisms.\textsuperscript{25,29,30}

The most common etiology for LGIB in anticoagulation and LVAD recipients is intestinal angiodysplasia.\textsuperscript{31,32} Angiodysplasia is a type of AVM with ectatic mucosal capillaries in the intestine wall, communi-cating with dilated and tortuous submucosal veins. The abnormal vessels may be single or multiple, with 80\% of these lesions located in the right colon and cecum.\textsuperscript{32,33} Angiodysplasia is uncommon in young patients. In patients older than 65, angiodysplasia is reported as an identifiable source of bleeding in 20\% of LGIB cases. Approximately 15\% of patients with angiodysplasia will suffer from massive bleeding.\textsuperscript{11,24,33} Angiodysplasia also has an increased prevalence in patients with certain predisposing conditions, such as end-stage renal disease,\textsuperscript{33} von Willebrand disease,\textsuperscript{34} and aortic stenosis.\textsuperscript{35} In LVAD recipients the reduction of pulsatility of blood flow is thought to cause intestinal hypoperfusion and therefore lead to the development of angiodysplasia. Interestingly, most recipients of LVAD also developed acquired von Willebrand syndrome as demonstrated by reduced high-molecular-weight von Willebrand factor multimer levels.\textsuperscript{11,24,35} It has been hypothesized that patients with Heyde syndrome, which refers to an association between aortic valve stenosis and GIB, may share similar pathophysiology with those LVAD recipients who suffer GIB. The etiology of Heyde syndrome is thought to be related to intestinal angiodysplasia and acquired von Willebrand syndrome.\textsuperscript{36,41} In patients with Heyde syndrome, stenotic aortic valve causes decreased pulsatility with an associated risk of angiodysplasia as well as the destruction of von Willebrand factor multimers proteins due to mechanical shearing at the stiffened valve, leading to the development of acquired von Willebrand syndrome and subsequent increased risk of GIB.\textsuperscript{42,43} Patients with a LVAD likely share similar pathophysiology as the device may affect similar hearing forces by the impeller.\textsuperscript{44–46}

Currently, the first-line treatment for angiodysplasia is endoscopic interventions. In some patients with LVAD, despite repeated endoscopic interventions, no definitive cure can be obtained.\textsuperscript{45} Clinical management of LGIB in LVAD recipients by interventional radiology has therefore remained an essential adjunctive therapy. Angiodysplasia presents with multiple lesions in more than 50\% cases, most commonly in the cecum and right colon on the antimesenteric border, so it is a frequently identifiable bleeding source in LGIB.\textsuperscript{37} Bleeding from angiodysplasia stops spontaneously in the majority of the cases, however in approximately 15\% of the patients it can be life-threatening, and requires immediate and appropriate management to achieve hemostasis. Recurrent angiodysplastic bleeding is also associated with an increased mortality rate. Particularly in patients with LVAD, a recurrent GIB may necessitate multiple blood transfusions, leading to the development of circulating antibodies, which subsequently reduces the probability of an organ donor match and simultaneously raises the risk of cellular rejection after heart transplantation and transfusion incompatibility.\textsuperscript{38}

To our knowledge, few clinical studies have been performed by far to address the outcomes of patients with LVAD induced GIB. Mehta et al. recently conducted a retrospective study including both upper and lower GIB patients in LVAD recipients, to evaluate clinical outcomes following mesenteric angiography.\textsuperscript{49} They observed a lower rate of a positive angiograms, decreased embolization efficacy, higher rates of repeat angiography procedures, and prolonged length of stay in GIB patients with LVADs. Further, they reported this patient population had higher rates of clinical failure following interventional radiology management, with a more frequent need for subsequent surgical intervention, compared to those without LVADs. More recently, a retrospective study was performed by our group to investigate the clinical outcome following superselective transarterial embolization as well as prophylactic embolotherapy of LGIB in LVAD recipients in comparison to patients in which no embolization was performed.\textsuperscript{50} Focusing only on LGIB, we found bleeding in LVAD recipients is more likely to be angiographically occult, therefore leading to more frequent prophylactic embolizations based on pre-procedural imaging compared to patients without LVADs. Our study also suggested that transarterial embolization has a lower success rate in treating LGIB in LVAD recipients, whereas prophylactic embolotherapy might be useful and safe when treating angiographically occult LGIB in this particular patient group (Fig. 2).

More future studies, ideally including prospective investigations with larger sample size on LGIB in LVAD recipients, should be performed to verify the findings from the limited numbers of prior studies, and to confirm that LGIB in LVAD recipients is a distinct entity from bleeding in patients receiving anticoagulation therapy. The incidence of bowel ischemia following embolotherapy in LVAD recipients is an important topic given LGIB in LVAD recipients tends to recur and therefore needs repetitive embolizations. Bowel infarct is the most feared complication following arterial embolization therapy in LGIB patients, and usually requires surgical bowel resection. Its incidence is estimated at 1.3\%-5\%.\textsuperscript{51,52} Risk of infarct is directly proportional to the extent of vascular territory embolized.\textsuperscript{15} Bowel ischemia occurs more often in the colon, because in contrast to the small intestine, the colon may have limited collateral flow through an incomplete marginal artery system on the colon wall.\textsuperscript{53} Within the large bowel, the cecum has the longest vasa recta with limited distal collateral sources. These specific arterial anatomical arrangements may further predispose the cecum to ischemia.\textsuperscript{54} Future studies should specifically give attention to cecal bleeding in LVAD recipients, to address the potential higher risk of bowel infarct following embolotherapy. If confirmed, cecal branches should be approached with greater caution when embolization of cecal bleeding is considered. Given the increasing LVAD use and its strong association with LGIB,
transcatheter arterial embolization and prophylactic embolotherapy by interventional radiologists may play an increasingly important role in this specific and challenging patient population.

4. Conclusion

Future studies need to be performed to verify the safety and efficacy of prophylactic embolotherapy for angiographically occult LGIB, with focus on bleeding etiologies, anatomic location, comorbidities, and embolization techniques/agents. More future studies, ideally including prospective investigations with larger sample size on LGIB in anticoagulation and LVAD recipients, should be performed to verify the findings from the limited numbers of prior studies, and to confirm that LGIB in LVAD recipients is a distinct entity from bleeding in patients receiving anticoagulation therapy. The incidence of bowel ischemia following embolotherapy in anticoagulation and LVAD recipients is an important topic given LGIB in LVAD recipients tends to recur and therefore need repetitive embolizations.

References

1. Laine L, Yang H, Chang SC, et al. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012;107:1190–1195. quiz 6.
2. Farrell JJ, Friedman LS. Review article: the management of lower gastrointestinal bleeding. Aliment Pharmacol Ther. 2005;21:1281–1298.
3. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1997;92:419–424.
4. Chen CY, Wu CC, Jao SW, et al. Colonic diverticular bleeding with comorbid diseases may need elective colectomy. J Gastrointest Surg. 2009;13:516–520.
5. Parkes BM, Obeid FN, Sorensen VJ, et al. The management of massive lower gastrointestinal bleeding. Am Surg. 1993;59:676–678.
6. Funaki B. Microcatheter embolization of lower gastrointestinal hemorrhage: an old idea whose time has come. Cardiovasc Interv Radiol. 2004;27:591–599.
7. Marion Y, Lebreton G, Le Pennec V, et al. The management of lower gastrointestinal bleeding. J Visc Surg. 2014;151:191–201.
8. Zuckerman DA, Bocchini TP, Birnbaum EH. Massive hemorrhage in the lower gastrointestinal tract in adults: diagnostic imaging and intervention. AJR Am J Roentgenol. 1993;161:703–711.
9. Koval G, Benner KG, Roach J, et al. Aggressive angiographic diagnosis in acute lower gastrointestinal hemorrhage. Dig Dis Sci. 1987;32:248–253.
21. Li S, Sun S, Wang S. Safety and outcome of prophylactic embolotherapy for lower gastrointestinal hemorrhage: results from a single-institution study. J Vasc Interv Radiol. 2010;21:477–483.

22. Filippone A, Cianci R, Milano A, et al. Obscure and occult gastrointestinal bleeding: comparison of different imaging modalities. Abdom Imag. 2012;37:41–52.

23. Gunderman R, Leef J, Ong K, et al. Scintigraphic screening prior to visceral arteriography in acute lower gastrointestinal bleeding. J Nucl Med. 1998;39:1081–1083.

24. Lalonde SD, Alba AC, Rigobon A, et al. Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD. J Card Surg. 2013;28:604–610.

25. Morgan JA, Faoro G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2012;31:715–718.

26. Aggarwal A, Pant R, Kumar S, et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg. 2012;93:1534–1540.

27. Shrode CW, Draper KV, Huang RJ, et al. Significantly higher rates of gastrointestinal bleeding and thromboembolic events with left ventricular assist devices. Clin Gastroenterol Hepatol. 2014;12:1461–1467.

28. Srulak JM, Lee D, Haft JW, et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant. 2014;33:60–64.

29. Schaffer JM, Arnaoutakis GJ, Allen JG, et al. Bleeding complications and blood product utilization with left ventricular assist device implantation. Ann Thorac Surg. 2011;91:740–747. discussion 7–9.

30. Singh G, Albedawi M, Kalra SS, et al. Features of patients with gastrointestinal bleeding after implantation of ventricular assist devices. Clin Gastroenterol Hepatol. 2015;13, 107–14.e1.

31. Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc. 2014;80:435–446.e1.